心力衰竭患者中伊伐布雷定临床疗效的影响因素  

Influence Factors of Clinical Efficacy in Patients with Congestive Heart Failure Treated by Ivabradine

作　　者：张文颖[1] 

机构地区：[1]广东省深圳市孙逸仙心血管医院,广东深圳518020

出　　处：《中国药业》2016年第15期4-9,共6页China Pharmaceuticals

摘　　要：目的探讨评估伊伐布雷定临床疗效的影响因素。方法通过查阅国内外文献及指南,从心率、β-受体阻断剂使用率、使用剂量等方面分析评估影响伊伐布雷定疗效的因素,考察伊伐布雷定在收缩性心力衰竭治疗中的使用证据。结果伊伐布雷定的临床疗效依赖于基础心率;β-受体阻断剂的使用率在评估伊伐布雷定的疗效上仍有优化空间;主要终点事件结果的决定性因素并非β-受体阻断剂的剂量,而是心率的绝对下降。结论指南所提及的大型临床试验中入组患者的基线心率、β-受体阻断剂的使用率及剂量等都可能给评估伊伐布雷定的临床疗效带来一定的影响,需要在临床实践中摸索更加贴近实际的药物联用方法 。Objective To investigate the influence factors of evaluating the outcomes of heart rate reduction by ivabradine in patients with congestive heart failure. Methods Through consulting literature materials at home and abroad, this article summarized the influence of evaluating the outcomes of heart rate reduction by ivabradine in patients with congestive heart failure, from heart rate, usage rate of beta- blocker and beta- blocker dose. Results The effect of ivabradine was depend on base line heart rate. There was still room for optimizing the usage rate of beta- bloeker. Heart rate reduction was more important than the achievement of target dose in predicting improved outcome. Conclusion Heart rate, usage rate of beta- blocker and beta- blocker dose of the patient from the clinical trials referred in the guideline affect the clinical efficacy of ivabradine. It is needed to grope the method of the usage of the combination of beta- blocker and ivabradine which is more close to the clinic.

关 键 词：伊伐布雷定 Β-受体阻断剂 心衰 疗效 临床试验 指南 

分 类 号：R969.3[医药卫生—药理学] R972.2[医药卫生—药学]